4.7 Editorial Material

Coexisting Genomic Alterations in Risk Stratification of KRAS(G12C)-Mutated Non-Small Cell Lung Cancer

Journal

CANCER DISCOVERY
Volume 13, Issue 7, Pages 1513-1515

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-23-0489

Keywords

-

Categories

Ask authors/readers for more resources

Negrao and colleagues demonstrated that coalterations in KEAP1, SMARCA4, and CDKN2A genes were linked to poor clinical outcomes in patients with KRAS (G12C)-mutated non-small cell lung cancer treated with sotorasib or adagrasib. Their study emphasizes the potential of integrating high-resolution real-world genomic data with clinical outcomes to enable risk-stratified precision therapies.
Negrao and colleagues showed that coalterations in three genes- KEAP1, SMARCA4, and CDKN2A- correlated to poor clinical outcomes in patients with KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib or adagrasib. Their study highlights how pooling high-resolution real-world genomic data with clinical outcomes can potentially facilitate risk-stratified precision therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available